143 related articles for article (PubMed ID: 17924396)
1. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
Dangoor D; Biondi B; Gobbo M; Vachutinski Y; Fridkin M; Gozes I; Rocchi R
J Pept Sci; 2008 Mar; 14(3):321-8. PubMed ID: 17924396
[TBL] [Abstract][Full Text] [Related]
2. Novel extended and branched N-terminal analogs of VIP.
Dangoor D; Rubinraut S; Fridkin M; Gozes I
Regul Pept; 2006 Nov; 137(1-2):42-9. PubMed ID: 16962672
[TBL] [Abstract][Full Text] [Related]
3. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma.
Bolin DR; Michalewsky J; Wasserman MA; O'Donnell M
Biopolymers; 1995; 37(2):57-66. PubMed ID: 7893947
[TBL] [Abstract][Full Text] [Related]
4. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors.
Igarashi H; Ito T; Mantey SA; Pradhan TK; Hou W; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2005 Oct; 315(1):370-81. PubMed ID: 15994369
[TBL] [Abstract][Full Text] [Related]
5. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
6. VPAC1 receptor binding site: contribution of photoaffinity labeling approach.
Couvineau A; Ceraudo E; Tan YV; Laburthe M
Neuropeptides; 2010 Apr; 44(2):127-32. PubMed ID: 20031208
[TBL] [Abstract][Full Text] [Related]
7. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
8. Novel analogs of VIP with multiple C-terminal domains.
Dangoor D; Rubinraut S; Fridkin M; Gozes I
Peptides; 2007 Sep; 28(9):1622-30. PubMed ID: 17481779
[TBL] [Abstract][Full Text] [Related]
9. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
[TBL] [Abstract][Full Text] [Related]
10. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
Langer I; Gregoire F; Nachtergael I; De Neef P; Vertongen P; Robberecht P
Peptides; 2004 Feb; 25(2):275-8. PubMed ID: 15063009
[TBL] [Abstract][Full Text] [Related]
11. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
El Zein N; Badran B; Sariban E
J Leukoc Biol; 2008 Apr; 83(4):972-81. PubMed ID: 18174366
[TBL] [Abstract][Full Text] [Related]
12. A complete substitutional analysis of VIP for better tumor imaging properties.
Bhargava S; Licha K; Knaute T; Ebert B; Becker A; Grötzinger C; Hessenius C; Wiedenmann B; Schneider-Mergener J; Volkmer-Engert R
J Mol Recognit; 2002; 15(3):145-53. PubMed ID: 12203840
[TBL] [Abstract][Full Text] [Related]
13. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
Grant S; Lutz EM; McPhaden AR; Wadsworth RM
J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462
[TBL] [Abstract][Full Text] [Related]
14. Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
de Maria S; Metafora V; Metafora S; Ravagnan G; Cartení M; Pontoni G; Facchiano A; Lepretti M; Severino B; Caliendo G; Santagada V; Langer I; Robberecht P
J Pept Sci; 2008 Jan; 14(1):102-9. PubMed ID: 17883247
[TBL] [Abstract][Full Text] [Related]
15. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
Couvineau A; Tan YV; Ceraudo E; Lacapère JJ; Murail S; Neumann JM; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
[TBL] [Abstract][Full Text] [Related]
17. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
Stark B; Andreae F; Mosgoeller W; Edetsberger M; Gaubitzer E; Koehler G; Prassl R
Eur J Pharm Biopharm; 2008 Sep; 70(1):153-64. PubMed ID: 18555674
[TBL] [Abstract][Full Text] [Related]
18. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.
Delgado M; Robledo G; Rueda B; Varela N; O'Valle F; Hernandez-Cortes P; Caro M; Orozco G; Gonzalez-Rey E; Martin J
Arthritis Rheum; 2008 Apr; 58(4):1010-9. PubMed ID: 18383379
[TBL] [Abstract][Full Text] [Related]
19. Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.
Pan CQ; Hamren S; Roczniak S; Tom I; DeRome M
Peptides; 2008 Mar; 29(3):479-86. PubMed ID: 17942192
[TBL] [Abstract][Full Text] [Related]
20. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
Tan YV; Couvineau A; Van Rampelbergh J; Laburthe M
J Biol Chem; 2003 Sep; 278(38):36531-6. PubMed ID: 12807902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
